Scroll To Top
Health

NIH launches
Phase II trial of HIV vaccine

NIH launches
Phase II trial of HIV vaccine

The National Institutes of Health this week launched a Phase II clinical trial of a vaccine aimed at preventing HIV infection, The Wall Street Journal reports. The vaccine, called HVTN 204, uses synthetic HIV genes to prime the immune system to recognize and attack the virus when it tries to enter the body. The vaccine focuses on three separate strains of HIV--strains A, B, and C--which represent more than 85% of the world's HIV cases, and is the first major experimental vaccine to focus on strains found in more than two regions of the world. "This is the first Phase II study of a vaccine candidate that is broadly relevant to the global AIDS pandemic," Gary Nabel, director of the Dale and Betty Bumpers Vaccine Research Center at the NIH, told the Journal. The vaccine trial will include 480 HIV-negative volunteers at 13 sites in the United States, South America, Africa, and the Caribbean. (Advocate.com)

Advocate Channel - The Pride StoreOut / Advocate Magazine - Fellow Travelers & Jamie Lee Curtis

From our Sponsors

Most Popular

Latest Stories

Outtraveler Staff